Objective To investigate the effect of Rosuvastatin on micro-inflammatory and serum lipids in hemodialysis patients. Method A total of 100 hemodialysis patients enrolled in our hospital from April 2014 to April 2016 was divided into control and treatment group. The control group received regular hemodialysis. The treat-ment group received regular hemodialysis combined with rosuvastatin. The general information ,micro inflammatory index ,serum lipids and clinical symptoms were compared between the two groups. There was no significant dif-ference between the two groups in terms of age,sexual,time of hemodialysis,primary disease,ultrafiltration vol-ume,MQSGA score,BUN,Scr,TC and TG. There was no significant difference between these two groups in terms of CRP ,IL-6 ,TNF-α,TC ,LDL ,TG before the treatment. The treatment group was significantly lower than that of control group ,in terms of CRP ,IL-6 ,TNF-α,TG ,LDL ,TC and BUA ,after treatment. In the 3-month treatment,50 patients in control and treatment group appears weakness:4 vs. 0(8%vs. 0%,P=0.041);fatigue symptom:7 vs. 1(14%vs. 2%,P=0.027);muscle spasm:8 vs. 2(16%vs. 4%,P=0.045);hypotension:5 vs. 0(4% vs. 2%,P = 0.021). Treatment group was remarkably lower than control group(P < 0.05). Conclusion Rosuvastatin can effectively alleviate the micro-inflammatory state of remission ,reduce serum lipid and uric acid in hemodialysis patients ,and improve the complications in hemodialysis.